Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan J Sullivan

Showing results (111-120 of 327) with videos related to

Pageof 33
Sort By:
The Lancet. Oncology|August 8, 2020
Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and researchDouglas B Johnson, Kerry L Reynolds, Ryan J Sullivan, et al.
Journal of Neuro-Oncology|April 13, 2015
Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor eraDaniel A Wattson, Ryan J Sullivan, Andrzej Niemierko, et al.
Nature Reviews. Disease Primers|April 3, 2025
Cutaneous melanomaAlpaslan Tasdogan, Ryan J Sullivan, Alexander Katalinic, et al.
Journal for Immunotherapy of Cancer|May 17, 2020
Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitisMeghan J Mooradian, Daniel Y Wang, Alexandra Coromilas, et al.
Journal of Cancer|October 6, 2025
Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced MelanomaRyan J Sullivan, Katy K Tsai, Anna C Pavlick, et al.
Journal of Translational Medicine|April 8, 2021
The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020Paolo A Ascierto, Joshua Brody, Lisa H Butterfield, et al.
Organic Letters|May 24, 2024
General and Scalable Synthesis of 2-Aryl and 2-Alkyl Pyrimidines via an Electronically Tuned S<sub>N</sub>Ar ApproachChandrasekhar Navuluri, Hsin Y Su, Ryan J Sullivan, et al.
Kidney Medicine|August 1, 2020
Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic MelanomaHarish Seethapathy, Halla Bates, Donald F Chute, et al.
CA: a Cancer Journal for Clinicians|March 26, 2026
Integrating multimodal management and molecular profiling in a patient with BRAF V600E-positive melanoma and brain metastasesDavid Gritsch, Riley M Fadden, Maura K Mahar, et al.
Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitorsHarriet Kluger, J Carl Barrett, Justin F Gainor, et al.
Pageof 33

Showing results (111-120 of 327) with videos related to

Sort By:
Pageof 33
The Lancet. Oncology|August 8, 2020
Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and researchDouglas B Johnson, Kerry L Reynolds, Ryan J Sullivan, et al.
Journal of Neuro-Oncology|April 13, 2015
Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor eraDaniel A Wattson, Ryan J Sullivan, Andrzej Niemierko, et al.
Nature Reviews. Disease Primers|April 3, 2025
Cutaneous melanomaAlpaslan Tasdogan, Ryan J Sullivan, Alexander Katalinic, et al.
Journal for Immunotherapy of Cancer|May 17, 2020
Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitisMeghan J Mooradian, Daniel Y Wang, Alexandra Coromilas, et al.
Journal of Cancer|October 6, 2025
Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced MelanomaRyan J Sullivan, Katy K Tsai, Anna C Pavlick, et al.
Journal of Translational Medicine|April 8, 2021
The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020Paolo A Ascierto, Joshua Brody, Lisa H Butterfield, et al.
Organic Letters|May 24, 2024
General and Scalable Synthesis of 2-Aryl and 2-Alkyl Pyrimidines via an Electronically Tuned S<sub>N</sub>Ar ApproachChandrasekhar Navuluri, Hsin Y Su, Ryan J Sullivan, et al.
Kidney Medicine|August 1, 2020
Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic MelanomaHarish Seethapathy, Halla Bates, Donald F Chute, et al.
CA: a Cancer Journal for Clinicians|March 26, 2026
Integrating multimodal management and molecular profiling in a patient with BRAF V600E-positive melanoma and brain metastasesDavid Gritsch, Riley M Fadden, Maura K Mahar, et al.
Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitorsHarriet Kluger, J Carl Barrett, Justin F Gainor, et al.
Pageof 33